Phase II/III Study of S-877503 in Pediatric Patients with Attention-deficit/Hyperactivity Disorder -Long term Extension Study-
Phase of Trial: Phase II/III
Latest Information Update: 25 Jan 2018
At a glance
- Drugs Guanfacine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions
- Sponsors Shionogi; Shire
- 19 Jan 2018 Status changed from active, no longer recruiting to completed.
- 10 Jan 2017 Status changed from recruiting to active, no longer recruiting.
- 03 Jun 2016 New trial record